1613 related articles for article (PubMed ID: 15640916)
21. Essential drugs in the new international economic environment.
Velásquez G; Boulet P
Bull World Health Organ; 1999; 77(3):288-92. PubMed ID: 10212525
[TBL] [Abstract][Full Text] [Related]
22. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
Halliburton M
Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
[TBL] [Abstract][Full Text] [Related]
23. Basic survival needs and access to medicines--coming to grips with TRIPS: conversion + calculation.
Van Puymbroeck RV
J Law Med Ethics; 2010; 38(3):520-49. PubMed ID: 20880239
[TBL] [Abstract][Full Text] [Related]
24. The GO License: only part of the solution.
Batson A; Milstien JB
Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
[TBL] [Abstract][Full Text] [Related]
25. Impact on access to medicines from TRIPS-Plus: a case study of Thai-US FTA.
Kessomboon N; Limpananont J; Kulsomboon V; Maleewong U; Eksaengsri A; Paothong P
Southeast Asian J Trop Med Public Health; 2010 May; 41(3):667-77. PubMed ID: 20578557
[TBL] [Abstract][Full Text] [Related]
26. Balancing public health, trade and intellectual monopoly privileges: recent Australian IP legislation and the TPPA.
Vines T; Crow K; Faunce T
J Law Med; 2012 Dec; 20(2):280-94. PubMed ID: 23431847
[TBL] [Abstract][Full Text] [Related]
27. Access to medicines and domestic compulsory licensing: learning from Canada and Thailand.
Kuek V; Phillips K; Kohler JC
Glob Public Health; 2011; 6(2):111-24. PubMed ID: 20234967
[TBL] [Abstract][Full Text] [Related]
28. A one-time-only combination: Emergency medicine exports and the TRIPS agreement under Canada's access to medicines regime.
Weber A; Mills L
Health Hum Rights; 2010 Jun; 12(1):109-22. PubMed ID: 20930258
[TBL] [Abstract][Full Text] [Related]
29. Intellectual property rights, the World Trade Organization and public health: the Brazilian perspective.
Viana JM
Conn J Int Law; 2002; 17(2):311-8. PubMed ID: 12688298
[No Abstract] [Full Text] [Related]
30. Taking TRIPS to India--Novartis, patent law, and access to medicines.
Mueller JM
N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
[No Abstract] [Full Text] [Related]
31. Unfair competition under the TRIPS agreement: protection of data submitted for the registration of pharmaceuticals.
Correa CM
Chic J Int Law; 2002; 3(1):69-85. PubMed ID: 15709300
[No Abstract] [Full Text] [Related]
32. Global patent police block cost-reduction efforts.
Kasper T
GMHC Treat Issues; 1999 Mar; 13(3):1-2. PubMed ID: 11366201
[TBL] [Abstract][Full Text] [Related]
33. Expanding drug access in Brazil: lessons for Latin America and Canada.
Cohen JC
Can J Public Health; 2006; 97(6):I15-8. PubMed ID: 17203728
[TBL] [Abstract][Full Text] [Related]
34. The WTO dispute settlement understanding: an unlikely weapon in the fight against AIDS.
Curti AM
Am J Law Med; 2001; 27(4):469-85. PubMed ID: 11837145
[No Abstract] [Full Text] [Related]
35. The new patent regime and disease priorities in India.
Gupta I; Guin P; Trivedi M
Glob Public Health; 2013; 8(1):37-54. PubMed ID: 22845021
[TBL] [Abstract][Full Text] [Related]
36. The Politics and Policies of Regulating Generics in Latin America: A Survey of Seventeen States.
Sweet CM
J Health Polit Policy Law; 2017 Jun; 42(3):485-512. PubMed ID: 28213391
[TBL] [Abstract][Full Text] [Related]
37. Is Compulsory Licensing Bad for Public Health? Some Critical Comments on Drug Accessibility in Developing Countries.
Guennif S
Appl Health Econ Health Policy; 2017 Oct; 15(5):557-565. PubMed ID: 28120166
[TBL] [Abstract][Full Text] [Related]
38. Patent implications in the pharmaceutical industry: Are static high prices leading to dynamic innovations?
Pandey E; Paul SB
Int J Risk Saf Med; 2019; 30(3):179-192. PubMed ID: 31450515
[TBL] [Abstract][Full Text] [Related]
39. How do public health safeguards in Indian patent law affect pharmaceutical patenting in practice?
Sampat BN; Amin T
J Health Polit Policy Law; 2013 Aug; 38(4):735-55. PubMed ID: 23645877
[TBL] [Abstract][Full Text] [Related]
40. Intellectual property rights, compulsory licensing and the TRIPS agreement: some ethical issues.
Schuklenk U
Monash Bioeth Rev; 2003 Apr; 22(2):63-8. PubMed ID: 15069958
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
